Eval & Claim CME Credits*

*CME/CE credits only available to participants that attended the LIVE session on Friday, December 4, 2020.

Webinars

Click the links below to view our presentations:
 

Welcome – About the MDS Foundation, Inc

Stephen Nimer, MD (MDSF Chairman) Sylvester Comprehensive Cancer Center, FL

Program Overview and Objectives

Mario Cazzola, MD University of Pavia, Italy

Challenges in MDS Diagnosis

Rafael Bejar, MD, PhD Moores Cancer Center, CA

Managing MDS in the Wake of a Global Pandemic

Amy DeZern, MD Johns Hopkins University School of Medicine, MD

Venetoclax in Higher-Risk MDS/AML

Katharina S. Götze, MD Technische Universität Müchen, Germany

Role of CAR T-Cells in Myeloid Malignancies: Lessons Learned from Lymphoid Malignancies

Saar Gill, MD, PhD University of Pennsylvania, PA

Targeted Therapies (enasidenib, ivosidenib, APR-246)

Stéphane de Botton, MD, PhD Gustave Roussy, France

Q&A with Stephane de Botton & Conclusions with Jane Churpek

Conclusions & Perspectives by Jane Churpek, MD University of Wisconsin Carbone Cancer Center, Madison, WI

ACTIVITY OVERVIEW

Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).

AGENDA TOPICS

• Challenges in MDS diagnosis
• Managing MDS in the wake of a global pandemic
• Venetoclax in higher-risk MDS/AML
• Role of CAR-T cells in myeloid malignancies: lessons learned from lymphoid malignancies
• Targeted therapies (enasidenib, ivosidenib, APR-246)

LEARNING OBJECTIVES

• Describe molecular profiling in diagnostic and prognostic evaluation of MDS.
• Evaluate the impact of COVID-19 on management of MDS patients
• Utilize venetoclax in higher-risk MDS patients
• Identify the prospects of adoptive cellular immunotherapy modalities and novel transplant-related approaches in MDS
• Describe targeted therapies in MDS.

FACULTY

Mario Cazzola, MD – Symposium Co-Chair

Professor of Hematology
Fondazione IRCCS Policlinico S. Matteo
University of Pavia
Pavia, Italy

Jane Churpek, MD – Symposium Co-Chair

Assistant Professor, Division of Hematology, Oncology, and Palliative Care
Department of Medicine
The University of Wisconsin School of Medicine and Public Health &
The University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, USA

Stephen D. Nimer, MD – MDSF Chairman

Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, U.S.A.

Rafael Bejar, MD, PhD

Associate Professor
University of California, San Diego
Moores Cancer Center
La Jolla, California, USA

Amy DeZern, MD, MHS

Associate Professor of Oncology
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, USA

Katharina S. Götze, MD

Technische Universität Müchen
Department of Medicine III
Munich, Germany

Saar Gill, MD, PhD

Assistant Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania
Philadelphia, PA, USA

Stéphane de Botton, Md, PhD

Head Multidisciplinary Committee
Hematology Department
Gustave Roussy
Villejuif Cedex, France